Tumour-promoting properties of mesenchymal stem cells in multiple myeloma: a potential risk for therapeutical use after haematopoietic stem cell transplantation in myeloma patients? Vrije Universiteit Brussel
Mesenchymal stem cells (MSCs) have recently been used in several pre-clinical and clinical studies to support hematopoiesis after hematopoietic stem cell transplantation (HSCT), to control graft versus host disease after allogeneic HSCT or for gene therapy in cancer. Although it is believed that MSCs have therapeutical potential for these particular applications,several studies have shown that MSCs might also play an active role in the ...